Fuchenchu Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fuchenchu Wang has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Amriti R. Lulla
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
14 shared publications - Asha S. Multani
Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas
14 shared publications - Aysegul A. Sahin
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
14 shared publications - C. Gary Marshall
Repare Therapeutics, Cambridge, Massachusetts
14 shared publications - Cansu Karakas
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
14 shared publications - Kelly K. Hunt
Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
14 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
This file contains all the information pertaining to supplementary methods that were referred to in the supplementary data.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
This file contains all the information pertaining to supplementary methods that were referred to in the supplementary data.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures and Legends from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
This file includes all the 8 supplementary figures and their corresponding figure legends referred to in the main text.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures and Legends from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
This file includes all the 8 supplementary figures and their corresponding figure legends referred to in the main text.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
Clinical and pathological characteristics of the 53 TNBC
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
Clinical and pathological characteristics of the 53 TNBC
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
Immune cell subset annotations and antibodies used for analysis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
Immune cell subset annotations and antibodies used for analysis.
- 2 February 2026
- Published by Elsevier in Pancreatology
- Vol. 26 (4) , 525-531
Long-term disease progression in pediatric acute recurrent and chronic pancreatitis: A report from INSPPIRE
- 2 February 2026
- Published by Elsevier in Pancreatology
- Vol. 26 (4) , 525-531
Long-term disease progression in pediatric acute recurrent and chronic pancreatitis: A report from INSPPIRE
- Open Access
- 18 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
This file contains all the information pertaining to supplementary methods that were referred to in the supplementary data.
- 18 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
This file contains all the information pertaining to supplementary methods that were referred to in the supplementary data.
- Open Access
- 18 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures and Legends from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
This file includes all the 8 supplementary figures and their corresponding figure legends referred to in the main text.
- 18 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures and Legends from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
This file includes all the 8 supplementary figures and their corresponding figure legends referred to in the main text.
- Open Access
- 18 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
Immune cell subset annotations and antibodies used for analysis.
- 18 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
Immune cell subset annotations and antibodies used for analysis.
- Open Access
- 18 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
Clinical and pathological characteristics of the 53 TNBC
- 18 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
Clinical and pathological characteristics of the 53 TNBC
- Open Access
- 18 November 2024
- Published by American Association for Cancer Research (AACR)
Data from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
Cyclin E is a regulatory subunit of CDK2 that mediates S phase entry and progression. The cleavage of full-length cyclin E (FL-cycE) to low–molecular weight isoforms (LMW-E) dramatically alters substrate specificity, promoting G1–S cell cycle transition and accelerating mitotic exit. Approximately 70% of triple-negative breast cancers (TNBC) express LMW-E, which correlates with poor prognosis. PKMYT1 also plays an important role in mitosis by inhibiting CDK1 to block premature mitotic entry, suggesting it could be a therapeutic target in TNBC expressing LMW-E. In this study, analysis of tumor samples of patients with TNBC revealed that coexpression of LMW-E and PKMYT1-catalyzed CDK1 phosphorylation predicted poor response to neoadjuvant chemotherapy. Compared with FL-cycE, LMW-E specifically upregulates PKMYT1 expression and protein stability, thereby increasing CDK1 phosphorylation. Inhibiting PKMYT1 with the selective inhibitor RP-6306 (lunresertib) elicited LMW-E–dependent antitumor effects, accelerating premature mitotic entry, inhibiting replication fork restart, and enhancing DNA damage, chromosomal breakage, apoptosis, and replication stress. Importantly, TNBC cell line xenografts expressing LMW-E showed greater sensitivity to RP-6306 than tumors with empty vector or FL-cycE. Furthermore, RP-6306 exerted tumor suppressive effects in LMW-E transgenic murine mammary tumors and patient-derived xenografts of LMW-E–high TNBC but not in the LMW-E null models examined in parallel. Lastly, transcriptomic and immune profiling demonstrated that RP-6306 treatment induced interferon responses and T-cell infiltration in the LMW-E–high tumor microenvironment, enhancing the antitumor immune response. These findings highlight the LMW-E/PKMYT1/CDK1 regulatory axis as a promising therapeutic target in TNBC, providing the rationale for further clinical development of PKMYT1 inhibitors in this aggressive breast cancer subtype.Significance: PKMYT1 upregulation and CDK1 phosphorylation in triple-negative breast cancer expressing low–molecular weight cyclin E leads to suboptimal responses to chemotherapy but sensitizes tumors to PKMYT1 inhibitors, proposing a personalized treatment strategy.
- 18 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
Cyclin E is a regulatory subunit of CDK2 that mediates S phase entry and progression. The cleavage of full-length cyclin E (FL-cycE) to low–molecular weight isoforms (LMW-E) dramatically alters substrate specificity, promoting G1–S cell cycle transition and accelerating mitotic exit. Approximately 70% of triple-negative breast cancers (TNBC) express LMW-E, which correlates with poor prognosis. PKMYT1 also plays an important role in mitosis by inhibiting CDK1 to block premature mitotic entry, suggesting it could be a therapeutic target in TNBC expressing LMW-E. In this study, analysis of tumor samples of patients with TNBC revealed that coexpression of LMW-E and PKMYT1-catalyzed CDK1 phosphorylation predicted poor response to neoadjuvant chemotherapy. Compared with FL-cycE, LMW-E specifically upregulates PKMYT1 expression and protein stability, thereby increasing CDK1 phosphorylation. Inhibiting PKMYT1 with the selective inhibitor RP-6306 (lunresertib) elicited LMW-E–dependent antitumor effects, accelerating premature mitotic entry, inhibiting replication fork restart, and enhancing DNA damage, chromosomal breakage, apoptosis, and replication stress. Importantly, TNBC cell line xenografts expressing LMW-E showed greater sensitivity to RP-6306 than tumors with empty vector or FL-cycE. Furthermore, RP-6306 exerted tumor suppressive effects in LMW-E transgenic murine mammary tumors and patient-derived xenografts of LMW-E–high TNBC but not in the LMW-E null models examined in parallel. Lastly, transcriptomic and immune profiling demonstrated that RP-6306 treatment induced interferon responses and T-cell infiltration in the LMW-E–high tumor microenvironment, enhancing the antitumor immune response. These findings highlight the LMW-E/PKMYT1/CDK1 regulatory axis as a promising therapeutic target in TNBC, providing the rationale for further clinical development of PKMYT1 inhibitors in this aggressive breast cancer subtype.Significance: PKMYT1 upregulation and CDK1 phosphorylation in triple-negative breast cancer expressing low–molecular weight cyclin E leads to suboptimal responses to chemotherapy but sensitizes tumors to PKMYT1 inhibitors, proposing a personalized treatment strategy.